

# Francisco J Esteva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8347926/publications.pdf>

Version: 2024-02-01

38  
papers

2,414  
citations

279798  
23  
h-index

345221  
36  
g-index

38  
all docs

38  
docs citations

38  
times ranked

4720  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2078-2099.	1.6	303
2	Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. Journal of the National Cancer Institute, 2008, 100, 1179-1183.	6.3	280
3	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, 2603-2614.	4.1	265
4	Clinical utility of gene-expression signatures in early stage breast cancer. Nature Reviews Clinical Oncology, 2017, 14, 595-610.	27.6	197
5	Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes. Oncotarget, 2014, 5, 9864-9876.	1.8	188
6	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 2100-2108.	1.6	165
7	Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2736-2740.	1.6	141
8	CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncology, The, 2017, 18, 917-928.	10.7	93
9	Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology, 2018, 36, 2804-2807.	1.6	93
10	Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Scientific Reports, 2017, 7, 41960.	3.3	73
11	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2016, 16, 113-122.e1.	2.4	49
12	Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis. Breast Cancer Research and Treatment, 2019, 173, 329-341.	2.5	49
13	Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process. Oncotarget, 2018, 9, 12868-12878.	1.8	46
14	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. Journal of the National Cancer Institute, 2017, 109, .	6.3	42
15	High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts. International Journal of Cancer, 2018, 143, 3027-3034.	5.1	41
16	Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. Cancer Chemotherapy and Pharmacology, 2000, 46, 382-386.	2.3	36
17	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2â€“positive metastatic breast cancer. Cancer, 2014, 120, 1932-1938.	4.1	35
18	Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers. Clinical Cancer Research, 2015, 21, 1098-1105.	7.0	35

#	ARTICLE	IF	CITATIONS
19	HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. <i>Molecular Oncology</i> , 2015, 9, 586-600.	4.6	31
20	DUSP4 is associated with increased resistance against anti-HER2 therapy in breast cancer. <i>Oncotarget</i> , 2017, 8, 77207-77218.	1.8	30
21	Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. <i>Oncology</i> , 2005, 19, 4.	0.5	30
22	Gene Signatureâ€“Guided Dasatinib Therapy in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5265-5271.	7.0	28
23	Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1003-1009.	6.4	28
24	Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2â€“) advanced breast cancer (ABC): Results from MONALEESA-3.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1000-1000.	1.6	21
25	Optimizing outcomes in HER2-positive breast cancer: the molecular rationale. <i>Oncology</i> , 2005, 19, 5-16.	0.5	20
26	What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e117-e125.	3.8	13
27	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019, 19, 268-277.e1.	2.4	13
28	Breast cancer risk in relation to plasma metabolites among Hispanic and African American women. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 687-696.	2.5	13
29	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7388-7395.	7.0	12
30	Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 921-930.	4.1	11
31	Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2â€“) advanced breast cancer (aBC) who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.. <i>Journal of Clinical Oncology</i> . 2016. 34. TPS624-TPS624.	1.6	11
32	The current status of docetaxel for metastatic breast cancer. <i>Oncology</i> , 2002, 16, 17-26.	0.5	6
33	Genome-Based Risk Prediction for Early Stage Breast Cancer. <i>Oncologist</i> , 2014, 19, 1019-1027.	3.7	5
34	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. <i>Clinical Cancer Research</i> , 2021, 27, 5343-5352.	7.0	5
35	Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS1124-TPS1124.	1.6	3
36	Genomic Signatures in Breast Cancer: Limitations of Available Predictive Data and the Importance of Prognosis. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 25-31.	0.3	3

#	ARTICLE	IF	CITATIONS
37	Detection of metastases in breast cancer: Is whole body PET/MR better than PET/CT?. Journal of Clinical Oncology, 2014, 32, 15-15.	1.6	0
38	Abstract 5469: Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition. , 2014,, .		0